Vimarsana
Biggest News Aggregation in the World

Page 30 - Immunic News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Immunic. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Immunic Today - Breaking & Trending Today

DGAP-News: Immunic, Inc. to Participate in Industry and Investor Conferences in June - Vimarsana News

DGAP-News: Immunic, Inc. to Participate in Industry and Investor Conferences in June

DGAP-News: Immunic, Inc. / Key word(s): Conference Immunic, Inc. to Participate in Industry and Investor Conferences in June 10.06.2021 / 12:30 The issuer is solely responsible

Immunic, Inc. to Participate in Industry and Investor Conferences in June - Vimarsana News

Immunic, Inc. to Participate in Industry and Investor Conferences in June

/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at...

Immunic, Inc. Announces Appointment of Inderpal Singh as General Counsel - Vimarsana News

Immunic, Inc. Announces Appointment of Inderpal Singh as General Counsel

Share this article NEW YORK, June 1, 2021 /PRNewswire/ --  Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, announced the appointment of Inderpal Singh as General Counsel, effective today. In his new role, Mr. Singh will be responsible for legal and compliance matters and will become part of the management team of Immunic. "Inderpal is a seasoned legal executive, having spent 20 years in-house, advising several of the world's largest life scien...

Immunic, Inc. Announces EMPhASIS Interim Analysis of 10 mg Cohort Confirms IMU-838's Dose Response in Relapsing-Remitting Multiple Sclerosis and Supports Phase 3 Dose Selection - Vimarsana News

Immunic, Inc. Announces EMPhASIS Interim Analysis of 10 mg Cohort Confirms IMU-838's Dose Response in Relapsing-Remitting Multiple Sclerosis and Supports Phase 3 Dose Selection

/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment...

DGAP-News: Immunic, Inc. to Participate in Scientific, Investor and Industry Conferences in April - Vimarsana News

DGAP-News: Immunic, Inc. to Participate in Scientific, Investor and Industry Conferences in April

DGAP-News: Immunic, Inc. to Participate in Scientific, Investor and Industry Conferences in April vom 13.04.2021, 12:30 Uhr Bild: pixabay.com Immunic, Inc. to Participate in Scientific, Investor and Industry Conferences in April 13.04.2021 / 12:30 Immunic, Inc. to Participate in Scientific, Investor and Industry Conferences in April NEW YORK, April 13, 2021 - Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced participation in t...